(Q34264200)

1 August 2017

1 reference

title

New immunosuppressants in BMT/GVHD. (English)

1 reference

1 August 2017

1 reference

N Basara

1

1 reference

1 August 2017

S Günzelmann

2

1 reference

1 August 2017

W Willenbacher

3

1 reference

1 August 2017

A A Fauser

4

1 reference

1 August 2017

M G Kiehl

5

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Transplantation Proceedings

1 August 2017

published in

1 reference

1 August 2017

volume

33

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

2220-2222

1 reference

A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901946-7

7 January 2021

Graft-vs.-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901946-7

7 January 2021

A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901946-7

7 January 2021

Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901946-7

7 January 2021

Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901946-7

7 January 2021

Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901946-7

7 January 2021

Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901946-7

7 January 2021

Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901946-7

7 January 2021

Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901946-7

7 January 2021

Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2801%2901946-7

7 January 2021

10.1016/S0041-1345(01)01946-7

Identifiers

DOI

1 reference

1 August 2017

1 reference